Cost Effectiveness of Colorectal Cancer Screening Strategies in Middle- and High-Income Countries: A Systematic Review
- PMID: 39817422
- DOI: 10.1111/jgh.16882
Cost Effectiveness of Colorectal Cancer Screening Strategies in Middle- and High-Income Countries: A Systematic Review
Abstract
Background and aim: Colorectal cancer (CRC) is a significant global health burden, and screening can greatly reduce CRC incidence and mortality. Previous studies investigated the economic effects of CRC screening. We performed a systematic review to provide the cost-effectiveness of CRC screening strategies across countries with different income levels.
Methods: We searched relevant scientific databases (PubMed, Embase, Ovid, Web of Science, Scopus) from January 1, 2010, to December 31, 2023. We selected English-language studies related to model-based economic evaluations of CRC screening strategies. Information such as the characters of screening tests, model characteristics, and key cost-effectiveness findings were collected. The net monetary benefit approach was used to compare the outcomes of various strategies.
Results: A total of 56 studies were identified, including 46 from high-income countries (HICs), 6 from upper-middle-income countries (UMICs), and 4 from lower-middle-income countries (LMICs). Most annual fecal occult blood tests and fecal immunochemical tests were cost-saving, and colonoscopy every 10 years was cost-saving. Other strategies involving multitarget fecal FIT-DNA detection, computed tomography colonography, and flexible sigmoidoscopy were cost-effective compared with no screening. Newer strategies such as magnetic resonance colonography every 5 years, annual urine metabolomic tests, and fecal bacterial biomarkers were cost-effective compared with no screening.
Conclusion: In our updated review, we found that common CRC screening strategies and magnetic resonance colonography continued to be cost-effective compared with no screening. Areas for further development include accurately modeling the natural history of colorectal cancer and obtaining more evidence from UMICs and LMICs.
Keywords: colorectal cancer; cost effectiveness; microsimulation; screening strategies.
© 2025 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
References
-
- H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249.
-
- N. Li, B. Lu, C. Luo, et al., “Incidence, Mortality, Survival, Risk Factor and Screening of Colorectal Cancer: A Comparison Among China, Europe, and Northern America,” Cancer Letters 522 (2021): 255–268.
-
- Cancer IAfRo. Globocan 2020: Cancer Fact Sheets‐Colorectal Cancer. (2020).
-
- N. Keum and E. Giovannucci, “Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies,” Nature Reviews. Gastroenterology & Hepatology 16, no. 12 (2019): 713–732.
-
- P. Kanth and J. M. Inadomi, “Screening and Prevention of Colorectal Cancer,” BMJ 374 (2021): n1855.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
